CLEC-2 is an immunoglobulin receptor expressed on the surface of platelets, and its only ligand in the human body, PDPN, has been identified and is highly expressed on tumor cells.105 Studies have indicated that selectively inhibiting platelet CLEC-2 could provide an innovative approach to preventing hematogenous tumor metastasis and reducing cancer-associated thromboembolism.471 The use of 5-nitrobenzoate compound 2CP to specifically inhibit PDPN/CLEC-2 interaction can suppress PDPN-mediated platelet activation and enhance the chemotherapy efficacy of cisplatin.472. Here, PDPN is linked to cancer.